Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.62 |
| ▸ | PRKDC | P78527 | 1/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30405764 | 1.00 | PIK3CA (0.62) | PIK3CAPRKDCCREBBPNR1H2MTOR | |
| SCHEMBL856320 | 0.88 | PIK3CA (0.49) | PIK3CAPRKDCCREBBPNR1H2MTOR | |
| SCHEMBL3749745 | 0.88 | PIK3CA (0.49) | PIK3CAPRKDCMTORRIPK1GPR142 | |
| SCHEMBL2724334 | 0.86 | PIK3CA (0.47) | PIK3CAPRKDCCREBBPMTORRIPK1 | |
| SCHEMBL856145 | 0.85 | NR1H2 (0.48) | PIK3CAPRKDCCREBBPNR1H2RIPK1 | |
| SCHEMBL9288018 | 0.85 | PIK3CA (0.51) | PIK3CAPRKDCCREBBPNR1H2MTOR | |
| SCHEMBL3765369 | 0.84 | PIK3CA (0.45) | PIK3CAPRKDCCREBBPNR1H2RIPK1 | |
| SCHEMBL856311 | 0.84 | PIK3CA (0.48) | PIK3CAPRKDCCREBBPNR1H2MTOR | |
| SCHEMBL3754730 | 0.84 | PIK3CA (0.67) | PIK3CAPRKDCCREBBPMTORGPR142 | |
| SCHEMBL3277263 | 0.83 | PIK3CA (0.60) | PIK3CACREBBPRIPK1GPR142USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118978535-A | C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors | 锐新医药公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118894869-A | C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors | 锐新医药公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-3788050-B1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-112771054-B | C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors | 锐新医药公司 | 2024-08-16 | — | — | CN | disclosed |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| CN-112368289-B | C26-linked rapamycin analogues as MTOR inhibitors | 锐新医药公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3788049-A1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112368289-A | C26-linked rapamycin analogs as MTOR inhibitors | 锐新医药公司 | 2021-02-12 | — | — | CN | disclosed |
| EP-3619216-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-110770243-A | Rapamycin analogs as MTOR inhibitors | 锐新医药公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | Revolution Medicines, Inc. | 2019-11-07 | — | — | US | disclosed |
| WO-2018204416-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | PIK3CA 16/4885PRKDC 480/4885CREBBP 1171/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | PIK3CA 60/4885PRKDC 1510/4885CREBBP 334/4885 |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PIK3CA 60/4885PRKDC 1510/4885CREBBP 334/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PIK3CA 58/4885PRKDC 1218/4885CREBBP 252/4885 |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | PIK3CA 60/4885PRKDC 1510/4885CREBBP 334/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3CA 58/4885PRKDC 1218/4885CREBBP 252/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | PIK3CA 1144/4885PRKDC 2175/4885CREBBP 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.